Why Rapport Therapeutics stock moves
Rapport Therapeutics rose, moving more than the market, which was roughly flat.
Written after the close on ·
Why today
16,437 news analyzed todayRapport Therapeutics rose, moving more than the market, which was roughly flat.
No company news from that session clearly explains the move.
Over the last five trading days the stock fell slightly, moving in line with a falling S&P 500.
Trading was around its usual level, and the stock stayed well below its highest close of the past year.
The next earnings report is due 9 March 2027.
Today's move of +3.04% was 1.3 times a normal day's 2.3%. S&P 500 moved +0.31% on the same day.
Rapport Therapeutics +3.04%S&P 500 +0.31%Much stronger than the market
What analysts expect, and how often they have been right
Analysts’ estimates for Rapport Therapeutics.
Rapport Therapeutics earned more than expected in 6 out of 8 reports.
For comparison, about 82% of reports from US companies beat the estimate in the last three years.
The share moved in the same direction as the earnings surprise in 6 out of 8 reports with a measured move, against about 55% of reports from US companies.
Ratings
Price targets
Latest price $24.44
Earnings against expectations, and the share’s reaction
Expected EPSAbove estimateBelow estimateAs expected$
Next reported quarter: expected earnings per share of -$1.17 (March 9). For the current fiscal year, expected earnings per share changed from -$4.09 three months ago to -$3.98 now. 2026 estimate: -$3.98. 2027 estimate: -$4.97.
Has the share price followed the business?
Price and earnings moved in the same direction: 1 out of 1 years. Across US companies, that happens in about 65% of years. In 2025, the price changed +71% and earnings per share went from -$3.78 to -$2.86.
Revenue, profit and market cap
RevenueProfitMarket capHatched bars: analysts’ estimates.$B
Assets, liabilities and market cap
AssetsLiabilitiesMarket cap$B
Price and earnings moved in the same direction: 1 out of 1 years.Market cap (Now): $1.4BRevenue 2025: $0.0M
What the key figures say about Rapport Therapeutics
The figures connect what Rapport Therapeutics earns with what investors pay.
The line shows the share price in the same year, on its own scale. Hatched bars: analysts’ estimates.
Profit divided by the number of shares. Each share represents this much of the earnings.
2022–2025: -$23.10–-$2.86. Peers: Intellia Therapeutics -$3.35, Zealand Pharma 38.64 DKK, Gubra -11.10 DKK. 2026 estimate: -$3.98 (-$4.51–-$3.29). 2027 estimate: -$4.97 (-$6.80–-$3.81).
What the company sold during the year.
2022–2025: $0.0M–$0.0M. Peers: Intellia Therapeutics $59.5M, Zealand Pharma 4.6 bn DKK, Gubra 271 m DKK. 2026 estimate: $20.0M ($20.0M–$20.1M). 2027 estimate: $0.0M ($0.0M–$0.0M).
Profit as a percentage of shareholders’ money in the company.
2022–2025: −25.6%–−23.0%. Peers: Intellia Therapeutics −55.4%, Zealand Pharma 16.3%, Gubra −16.1%.
More key figures
Market cap divided by shareholders’ equity, what remains after liabilities.
2022–2025: 2.12–2.99. Peers: Intellia Therapeutics 1.97, Zealand Pharma 0.90, Gubra 4.75.
Cash left after investments, divided by the number of shares.
2022–2025: -$1.84–-$0.81. Peers: Intellia Therapeutics -$2.48, Zealand Pharma -27.61 DKK, Gubra 103.13 DKK.
The percentage of assets financed by shareholders’ equity.
2022–2025: −31.8%–97.0%.
What to watch next, and why
The earnings report shows how Rapport Therapeutics's revenue and profit have changed.
- Earnings report
The earnings report shows how Rapport Therapeutics's revenue and profit have changed.
Add to calendar
Earnings report
Next report: · Add to calendar · Google Calendar
On its last 10 report days Rapport Therapeutics usually moved about 3.0%. On a normal day it moves 2.3%.
+1.93% +0.57% +7.74% −2.98%
$10,000 in Rapport Therapeutics bought on June 7, 2024 is worth $11,800 today, with dividends reinvested.
The same amount in S&P 500 with dividends would have become $14,200.
What would $10,000 in Rapport Therapeutics be worth today? →
What would $10,000 in Rapport Therapeutics be worth today?
$11,800
with dividends reinvested, bought on June 7, 2024. The same amount in S&P 500 with dividends would have become $14,200.
At worst it was worth $3,440 (March 3, 2025).
The five biggest days of the journey
· +119.2% · the whole market rose 0.2% the same day
· +39.7% · the whole market fell 1.2% the same day
· +30.2% · the whole market rose 0.6% the same day
· −28.7% · the whole market fell 1.8% the same day
· +25.9% · the whole market rose 0.3% the same day
Earlier days
−2.44% market −2.70% Rapport Therapeutics fell slightly over the week, moving in line with a sharp drop in the S&P 500. Read →
Rapport Therapeutics fell slightly over the week, moving in line with a sharp drop in the S&P 500.
Its latest earnings release on 4 November, showing a smaller loss than analysts expected, was the main company news, though the stock traded up that day.
Analysts then trimmed their price targets, the prices they see as fair, on 5 and 6 November, citing concerns about safety and higher drop-out rates in its bipolar mania study.
The next earnings report is due in March 2027, and the company expects initial data from a long-term safety study in the fourth quarter of 2026.
−8.52% market −4.41% Rapport Therapeutics fell sharply, after company news. Read →
Rapport Therapeutics fell sharply, after company news.
The stock fell more than the S&P 500 and the Healthcare sector that day.
The main driver was likely analyst price target cuts, including Wells Fargo's cut citing safety concerns.
UBS also lowered its price target but kept its buy rating.
The move was very big, about four times a normal daily swing for the stock.
Learn more · Why do stocks go up and down?